Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Up 4.3% - Should You Buy?

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Get Free Report) were up 4.3% on Tuesday . The stock traded as high as $17.47 and last traded at $17.47. Approximately 90,922 shares were traded during trading, a decline of 79% from the average daily volume of 428,566 shares. The stock had previously closed at $16.75.

Wall Street Analysts Forecast Growth

CNTA has been the topic of several research reports. B. Riley began coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a "buy" rating and a $33.00 price objective on the stock. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $11.00 to $26.00 in a research report on Thursday, September 19th. Guggenheim upped their price target on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research report on Friday, November 15th. Jefferies Financial Group raised their price objective on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Finally, BMO Capital Markets raised their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an "outperform" rating in a report on Monday, September 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals has an average rating of "Buy" and a consensus price target of $25.83.

Centessa Pharmaceuticals Trading Up 5.1 %

The company has a market capitalization of $2.32 billion, a PE ratio of -11.50 and a beta of 1.52. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm's 50 day simple moving average is $16.56 and its 200-day simple moving average is $13.46.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Karen M. Anderson sold 10,624 shares of the business's stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $17.32, for a total transaction of $184,007.68. Following the transaction, the insider now directly owns 71,525 shares in the company, valued at $1,238,813. The trade was a 12.93 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Saurabh Saha sold 87,496 shares of the firm's stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $18.46, for a total value of $1,615,176.16. Following the sale, the chief executive officer now directly owns 575,661 shares of the company's stock, valued at $10,626,702.06. This trade represents a 13.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 374,642 shares of company stock valued at $6,375,876. Corporate insiders own 11.59% of the company's stock.

Institutional Trading of Centessa Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company's stock worth $40,000 after purchasing an additional 826 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company's stock valued at $48,000 after purchasing an additional 1,509 shares during the period. Quarry LP lifted its stake in shares of Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company's stock worth $87,000 after buying an additional 3,108 shares during the last quarter. Sandia Investment Management LP bought a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth $90,000. Finally, Fred Alger Management LLC acquired a new position in Centessa Pharmaceuticals in the 2nd quarter valued at $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.